This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Stratify Genomics

Profile

United States

Stratify Genomics sells Prompt, a risk stratification test for prostate cancer. Controversial recommendations have led to a 4x rise in metastatic prostate cancer. Using a patented SNP-based assay validated in the largest trials of our time, Prompt and our recommended screening frequency is 2x more efficient as annual PSA and 3x more effective than family history at detecting eventual cancer.

Presenter: Martyn Gross, President, Stratify Genomics

Contact